Know Cancer

forgot password

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Phase 2
18 Years
Not Enrolling
Waldenström's Macroglobulinemia

Thank you

Trial Information

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

This is a phase II study in relapsed/refractory WM patients treated with perifosine. It is
designed to assess the proportion of overall confirmed responses (CR + PR + MR) using a
two-stage phase II study design to permit early stopping of the trial if there is strong
evidence that the study regimen is inactive. In addition, it will assess toxicity of this
drug in patients with WM. Patients will receive perifosine 150 mg qhs daily. Patients will
be assessed by serum immunoelectrophoresis and IgM level at least every 4 weeks.

Patients will take three 50 mg tablets of perifosine qhs daily (for 28 days cycles) with
food. Patients may need anti-emetics and/or anti-diarrheas. All patients should continue
therapy unless disease progression is documented on two occasions at least 1 week apart.
Patients with progressive disease or who refuse further therapy will be discontinued from
the protocol. Dose modifications for toxicity will be performed.

Standard criteria for evaluation of response in WM recommended by the Second International
WM Workshop will be used in this study.

Inclusion Criteria:

- Age >= 18 years.

- Must have received prior therapy for their WM and have relapsed or refractory WM. Any
number of prior therapies is acceptable.

- Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a
minimum IgM level of > 2 times the upper limit of each institution's normal value is
required and over 10% of lymphoplasmacytic cells in the bone marrow.

- ECOG Performance Status (PS) 0, 1, or 2.

- The following laboratory values obtained 14 days prior to registration

- ANC >= 1 x109/L

- PLT >= 75 x109/L

- Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal patient
is eligible.)

- AST <= 3 x upper limit of normal (ULN)

- Creatinine <= 2 x ULN

- Ability to provide informed consent.

- Life expectancy >= 12 weeks.

Exclusion Criteria:

- Uncontrolled infection.

- Other active malignancies.

- CNS involvement.

- Cytotoxic chemotherapy ≤ 3 weeks, or biologic therapy ≤ 2 weeks, or corticosteroids ≤
2 weeks, prior to registration. Patients may be receiving chronic corticosteroids if
they are being given for disorders other than WM such as auto-immune diseases.
Plasmapheresis is not considered as an active therapy and can be used at the
physician's discretion.

- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy
considered investigational.

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate
contraception (condoms, diaphragm, birth control pills, injections, intrauterine
device (IUD), or abstinence, etc.)

- Known to be HIV positive.

- Radiation therapy ≤ 2 weeks prior to registration.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate

Outcome Time Frame:

Every 4 weeks

Safety Issue:


Principal Investigator

Irene M Ghobrial, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Dana-Farber Cancer Institute


United States: Food and Drug Administration

Study ID:

Perifosine 221



Start Date:

October 2006

Completion Date:

October 2011

Related Keywords:

  • Waldenstrom's Macroglobulinemia
  • Waldenström's Macroglobulinemia
  • Perifosine
  • Waldenstrom Macroglobulinemia



Dana-Farber Cancer Institute Boston, Massachusetts  02115